Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage. [electronic resource]
Producer: 20090220Description: 61-4 p. digitalISSN:- 1537-453X
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carboplatin -- administration & dosage
- Drug Therapy, Combination
- Etoposide -- administration & dosage
- Female
- Granulocyte Colony-Stimulating Factor -- therapeutic use
- Humans
- Lenograstim
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Prognosis
- Prospective Studies
- Quality of Life
- Recombinant Proteins -- therapeutic use
- Safety
- Small Cell Lung Carcinoma -- drug therapy
- Survival Rate
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.